Scopus BioPharma (Scopus BioPharma) Earnings per Share (Diluted) : $-0.32 (TTM As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Scopus BioPharma Earnings per Share (Diluted)?

Scopus BioPharma's Earnings per Share (Diluted) for the three months ended in Jun. 2023 was $-0.07. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.32.

Scopus BioPharma's EPS (Basic) for the three months ended in Jun. 2023 was $-0.07. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.32.

Scopus BioPharma's EPS without NRI for the three months ended in Jun. 2023 was $-0.07. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.32.

During the past 3 years, the average EPS without NRIGrowth Rate was -45.10% per year.

During the past 6 years, Scopus BioPharma's highest 3-Year average EPS without NRI Growth Rate was -45.10% per year. The lowest was -229.40% per year. And the median was -137.25% per year.

Scopus BioPharma Earnings per Share (Diluted) Historical Data

The historical data trend for Scopus BioPharma's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scopus BioPharma Earnings per Share (Diluted) Chart

Scopus BioPharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-0.05

-0.18

-0.81

-1.56

-0.55

Scopus BioPharma Quarterly Data
	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-0.16	-0.09	-0.08	-0.08	-0.07

Competitive Comparison of Scopus BioPharma's Earnings per Share (Diluted)

For the Biotechnology subindustry, Scopus BioPharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scopus BioPharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scopus BioPharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Scopus BioPharma's PE Ratio falls into.

Scopus BioPharma Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Scopus BioPharma's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-11.61	-	0)	/	21.094
	=	-0.55

Scopus BioPharma's Earnings Per Share (Diluted) for the quarter that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-2.617	-	0)	/	39.743
	=	-0.07

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Scopus BioPharma (OTCPK:SCPS) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Scopus BioPharma Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Scopus BioPharma's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Scopus BioPharma (Scopus BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 300, New York, NY, USA, 10170

Website

https://www.scopusbiopharma.com

Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.

Executives

Ira Scott Greenspan	director	888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
Joshua R Lamstein	director, officer: Chairman	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Alan M Horsager	officer: See Remarks	1021 N EVERETT STREET, GLENDALE CA 91207
Robert J Gibson	director, officer: Vice Chairman	71 LANTERN RIDGE RD, NEW CANAAN CT 06840
Lesley Russell	director	41 MOORES RD., FRAZER PA 19355
Iv David Weild	director	22 ORIOLE AVENUE, BRONXVILLE NY 10708
David S. Battleman	director	C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
David A. Buckel	director	SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601
Raphael Hofstein	director	C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120
Paul Hopper	director	7982 DOUG HILL, SAN DIEGO CA 92127
Ashish P Sanghrajka	director, officer: President	101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005